News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

|Poll|June 24, 2015

Lung Mass Found in 51-Year-Old Patient

Author(s)Cesar A. Moran, MD

A 51-year-old man presents with a lung mass. What is your diagnosis?

A 51-year-old man presents with a lung mass.

What is your diagnosis?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related Content

OncoPrism-NSCLC was found to be a predictive biomarker of immune checkpoint inhibitor benefit vs a general prognostic tool in patients with NSCLC.

OncoPrism-NSCLC Test Predicts Key Clinical Outcomes in Lung Cancer

December 19th 2025

Expert teams debate cutting-edge lung cancer treatments, exploring trial data and innovative strategies for improving patient outcomes in NSCLC and SCLC.

The Differing Opinions of Lung Cancer Care: The Phantoms vs The Accelerators

ByONCOLOGY Staff

December 13th 2025

With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.

Envisaging Sequencing Considerations in EGFR-Mutated Lung Cancer

ByGirindra Raval, MD

December 11th 2025

An oncologist at the Georgia Cancer Center discussed the evolution of treatment strategies and emerging therapies for patients with EGFR-mutated disease.

Surveying the Treatment Landscape for EGFR-Mutated Lung Cancer

ByRoman Fabbricatore

December 9th 2025

Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.

Defining the Role of Perioperative Therapy Across Lung Cancer Subtypes

ByGirindra Raval, MD

December 5th 2025

Trending on CancerNetwork

Nab-Sirolimus Regimens Show Promise in HR+/HER2-Negative Breast Cancer

Spotlighting the Top 10 FDA Oncology Approvals in 2025

Ivosidenib Combo Shows Preliminary Activity in IDH1-Mutated AML

Human Coaching Via Mobile App May Reduce Postgastrectomy Symptoms

What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting